Savara Inc. SVRA

What this company does

Our sole program, molgramostim inhalation solution ("MOLBREEVI" or "molgramostim"), is an investigational inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor ("GM-CSF") in Phase 3 development for autoimmune pulmonary alveolar proteinosis (“autoimmune PAP”). MOLBREEVI is delivered via a proprietary eFlow® Nebulizer System (PARI Pharma GmbH, “PARI”). In March 2025, the biologics license application (“BLA”) for MOLBREEVI in autoimmune PAP was submitted to the U.S. Food and Drug Administration (“FDA”). In February 2024, we entered into a Master Services Agreement with FUJIFILM Diosynth Biotechnologies (“Fujifilm”) to complete a technology transfer of the drug substance manufacturing process from GEMA Biotech S.A. (“GEMA”) and to manufacture commercial supply of MOLBREEVI.

Written from the business description in Savara Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 13 March 2026. Every sentence was checked against that document before publication.